Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluconazole + meropenem
- Development stage
- Preclinical
- Lead developer
- Sumitomo Pharma
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of fluconazole (a triazole antifungal) and meropenem (a carbapenem antibiotic). This combination has been studied for its effectiveness against polymicrobial biofilms, particularly those formed by Pseudomonas aeruginosa and Candida albicans. Research indicates that the combination therapy may be more effective than monotherapy with either drug alone in reducing biofilm formation.
02
Targets
Beyond the preview
Go deeper on fluconazole + meropenem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluconazole + meropenem.